GHRP2
GHRP-2
A synthetic hexapeptide, D-Ala-D-2-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2, and an agonist at the growth hormone secretagogue receptor type 1a. The D-amino acids at three positions are what make it resistant to the peptidases that would clear an all-L sequence.
No registered human study names GHRP-2 as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains GHRP-2. 23 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names GHRP-2; the registry search is fuzzy, so every match is re-checked. None of this says whether GHRP-2 works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
23
Readership
73
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of GHRP-2 in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What GHRP-2 is, and what it has been studied for
GHRP-2 is classified by ChEMBL as a protein, and appears in trial registrations under KP-102.
No registered trial names GHRP-2 as an intervention, so there is no condition it has been formally studied in. It does have a literature: 23 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying GHRP-2?
Papers published each year that name GHRP-2 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 4 | 0 | Yes |
| 2018 | 4 | 0 | Yes |
| 2019 | 5 | 0 | Yes |
| 2020 | 4 | 0 | Yes |
| 2021 | 2 | 0 | Yes |
| 2022 | 2 | 0 | Yes |
| 2023 | 1 | 0 | Yes |
| 2024 | 1 | 0 | Yes |
| 2025 | 3 | 0 | Yes |
| 2026 | 2 | 0 | No |
23 papers between 2017 and 2026. A paper counts when “GHRP-2” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on GHRP-2
23 indexed papers name GHRP-2 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Ipamorelin, the first selective growth hormone secretagogue
- Growth hormone-releasing peptides
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
- Detection of GHRP-2 and GHRP-6 in urine samples from athletes
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN
- GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans
- Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin
- Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men
Collected 2026-08-02from PubMed, phrase-matched on “GHRP-2” in title and abstract. Run the same search.
About GHRP-2
A synthetic hexapeptide, D-Ala-D-2-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2, and an agonist at the growth hormone secretagogue receptor type 1a. The D-amino acids at three positions are what make it resistant to the peptidases that would clear an all-L sequence.
- Also known as
- Pralmorelin · KP-102
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.